ValiRx Regulatory News (VAL)

25 February 2011

ValiRx Plc

("ValiRx" or the "Company")

Website Update

The Company announces that it has today uploaded a document on its AIM Rule 26 website (www.valirx.com) responding to frequently asked questions received from shareholders in relation to its recent announcements on the launch of its chlamydia self-check health screening product (14 February 2011) and issue of equity (16 February 2011).

For more information, please contact:

Notes for Editors

ValiRx Plc

ValiRx Plc is a biopharmaceutical company developing novel technologies and products in oncology therapeutics and diagnostics. The product focus is in the epigenomic analysis and treatment of cancer, but the technologies can be applied to other fields as well, such as neurology and inflammatory diseases.

The Company listed on AIM in October 2006 and is creating a portfolio of innovative products through investment in specific development projects. It actively manages projects within this portfolio as a trading company and is not an investment vehicle. The ValiRx business model spreads the risks of life science technology developments by minimising financial exposure and running a set of projects to defined commercial endpoints. This maximises returns to shareholders by adding value at the earlier stages where value increases per investment unit are the greatest.

The Company operates through the following divisional companies:

·; ValiMedix is the sales and distribution division of ValiRx

·; ValiPharma is the therapeutics division with two embedded technologies primarily directed at the treatment of cancers. Of particular note is GeneICE, ValiRx's technology for controlling rebellious genes, which was awarded a Eurostars grant to the value of €1.2 million to fund the development of the GeneICE products through preclinical stages in cancer treatments. ValiRx is leading a consortium of biotechnology companies that are completing pre-clinical studies based on ValiRx's GeneIce technology platform, prior to entering clinical trials.

In parallel, during the course of 2010, the Company has launched a range of home self-diagnostic kits that screen for high prevalence conditions, such as diabetes, urinary infections, high cholesterol, among other serious conditions. The Company has reported that sales of these products are in line with expectations and continuing to show an upward trend. Additionally, ValiRx hopes to continue the expansion of its range in subsequent quarters, further generating incremental revenue as a consequence.